Organon (OGN) said Monday it finalized the acquisition of Dermavant Sciences from Roivant (ROIV).
Dermavant develops and commercializes treatments in the immuno-dermatology space, including Vtama, which was approved by the US Food and Drug Administration to treat plaque psoriasis in adults, Organon said.
Price: 17.37, Change: +0.21, Percent Change: +1.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments